By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.